ANB020-006: A Phase 2, randomized, double-blind, placebo-controlled, parallel group, multiple dose study designed to assess the efficacy of different doses and dose regimens of etokimab compared to placebo in adults with moderate to severe chronic rhinosinusitis with nasal polyposis (CRSwNP). This study will also assess the safety, tolerability, and pharmacokinetics (PK) of etokimab. The effects of etokimab on subjects with moderate to severe CRSwNP will be monitored over 24 weeks.